Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related
Market Panic Has Created 'Compelling' Opportunities In Biotech
Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing
Related ACAD
Morning Market Gainers
Benzinga's Top #PreMarket Gainers
Premarket Biotech Digest: Shorts Targeting Biotech, Anavex's Promise, Zarxio Launch (Seeking Alpha)

Analysts at Deutsche Bank initiated coverage on shares of Sarepta Therapeutics (NASDAQ: SRPT) with a “buy” rating. The target price range for Sarepta Therapeutics is set to $45. Sarepta Therapeutics' shares closed at $33.03 yesterday.

Jefferies initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) with a “buy” rating. The target price for ACADIA Pharmaceuticals is set to $13. ACADIA Pharmaceuticals' stock closed at $6.18 yesterday.

Topeka Capital initiated coverage on shares of Schnitzer Steel Industries (NASDAQ: SCHN) with a “hold” rating. The target price for Schnitzer Steel Industries is set to $27. Schnitzer Steel Industries' shares closed at $28.60 yesterday.

Analysts at Bank of America initiated coverage on shares of Pluristem Therapeutics (NASDAQ: PSTI) with a “hold” rating. The target price for Pluristem Therapeutics is set to $3.50. Pluristem Therapeutics' shares closed at $3.17 yesterday.

Latest Ratings for SRPT

DateFirmActionFromTo
Sep 2015SunTrust Robinson HumphreyMaintainsNeutral
Aug 2015Roth CapitalReiteratesBuy
Aug 2015Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ACAD + PSTI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters